A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Richard Ghalie, MD
MEI Pharma
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- Scripps Cancer Center-Mercy
San Diego, California, United States
- Georgia Cancer Center at Augusta University
Augusta, Georgia, United States
- Georgia Cancer Center
Augusta, Georgia, United States
- Pontchartrain Cancer Center
Covington, Louisiana, United States
- Rcca Md Llc (the Center for Cancer and Blood Disorders)
Bethesda, Maryland, United States
- Michigan Center of Medical Research
Farmington Hills, Michigan, United States
- Michigan State University, Breslin Cancer Center
Lansing, Michigan, United States
- University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota, United States
- Mercy Medical Research Institute
Springfield, Missouri, United States
- New Mexico Cancer Care Alliance
Albuquerque, New Mexico, United States
- University of Rochester Medical Center
Rochester, New York, United States
- Stony Brook University
Stony Brook, New York, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Southeastern Medical Oncology Center
Goldsboro, North Carolina, United States
- Oncology Hematology Care
Cincinnati, Ohio, United States
- University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
- Cancer Centers of Southwest Oklahoma
Lawton, Oklahoma, United States
- Oklahoma Cancer Specialists and Research Institute
Tulsa, Oklahoma, United States
- Providence Portland Medical Center
Portland, Oregon, United States
- Ut Southwestern Medical Center
Dallas, Texas, United States
- Uva Health System Division of Hematology & Oncology
Charlottesville, Virginia, United States
- Swedish Cancer Institute
Seattle, Washington, United States
- Universityof Wisconsin Clinical Science Center
Madison, Wisconsin, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Jun 2017
- Primary completion
- 1 Dec 2020
- Completion
- 1 Dec 2020
- Last update posted
- 2 Mar 2022
- Registered enrollment
- 64
- Registry id
- NCT03151304
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.